Use of Wearables Following Cystectomy- Part II
Launched by UNIVERSITY OF PITTSBURGH ·
Trial Information
Current as of September 25, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is testing whether it’s practical to use a Fitbit Sense 2 wearable and a short daily smartphone questionnaire to monitor people after cystectomy (removal of the bladder) with urinary diversion. Up to 50 adults at the University of Pittsburgh/UPMC will wear the Fitbit and complete daily questions for about 30 days after hospital discharge (and may also do pre-surgery monitoring for about two weeks). The goal is to see if real-time data from the wearable and the surveys can trigger a health care team to contact a patient within 24 hours of any concerning signals, with the aim of catching problems early and reducing the chance of unexpected readmission.
Eligible participants are adults 18 or older, English-speaking, who own a smartphone and are scheduled for cystectomy with urinary diversion at a UPMC hospital, with reliable internet access. Exclusion criteria include lack of internet or participation in another interventional study. Participants should expect to set up and wear the device, complete daily smartphone surveys, and receive automated alerts if something looks concerning, prompting a provider follow-up within 24 hours. The study is a feasibility effort led by the University of Pittsburgh/UPMC, with results not yet available and plans to share de-identified data for future research after publication.
Gender
ALL
Eligibility criteria
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Matthew R Epstein, MD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported